News/ News/ Oncology German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy Catherine Longworth cancer, cancer immunotherapy, CatylYm, financing, Oncology 0 Comment CatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy Share X German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy https://pharmaphorum.com/news/german-biotech-catalym-raises-e50-million-for-gdf-15-inhibitor-immunotherapy/